GILEAD SCIENCES INC Insider Trading for February 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in GILEAD SCIENCES INC for February 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 20.71 | 6,650 | 137,688 | 33,350 | |
| Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Sell | S | 90.61 | 6,650 | 602,557 | 103,873 | 110.5 K to 103.9 K (-6.02 %) |
| Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 20.71 | 6,650 | 137,688 | 110,523 | 103.9 K to 110.5 K (+6.40 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 90.72 | 6,250 | 567,000 | 84,688 | 90.9 K to 84.7 K (-6.87 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 91.15 | 26,808 | 2,443,549 | 49,484 | 76.3 K to 49.5 K (-35.14 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 35,174 | 0 | 76,292 | 41.1 K to 76.3 K (+85.54 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 13,146 | 0 | 41,118 | 28 K to 41.1 K (+47.00 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 76.02 | 248 | 18,854 | 27,972 | 27.7 K to 28 K (+0.89 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Payment of Exercise | F | 91.15 | 45,433 | 4,141,218 | 1,058,963 | 1.1 M to 1.1 M (-4.11 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 0.00 | 58,794 | 0 | 1,104,396 | 1 M to 1.1 M (+5.62 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 0.00 | 16,246 | 0 | 1,045,602 | 1 M to 1 M (+1.58 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 76.02 | 248 | 18,854 | 1,029,356 | 1 M to 1 M (+0.02 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Payment of Exercise | F | 91.19 | 122,901 | 11,207,342 | 4,019,727 | 4.1 M to 4 M (-2.97 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 154,328 | 0 | 4,142,628 | 4 M to 4.1 M (+3.87 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 39,986 | 0 | 3,988,300 | 3.9 M to 4 M (+1.01 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 76.02 | 248 | 18,854 | 3,948,314 | 3.9 M to 3.9 M (+0.01 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 91.15 | 7,395 | 674,054 | 61,122 | 68.5 K to 61.1 K (-10.79 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 9,554 | 0 | 68,517 | 59 K to 68.5 K (+16.20 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 9,932 | 0 | 58,963 | 49 K to 59 K (+20.26 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 76.02 | 248 | 18,854 | 49,031 | 48.8 K to 49 K (+0.51 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Payment of Exercise | F | 91.15 | 40,716 | 3,711,263 | 191,940 | 232.7 K to 191.9 K (-17.50 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 52,914 | 0 | 232,656 | 179.7 K to 232.7 K (+29.44 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 14,326 | 0 | 179,742 | 165.4 K to 179.7 K (+8.66 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 76.02 | 248 | 18,854 | 165,416 | 165.2 K to 165.4 K (+0.15 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Payment of Exercise | F | 91.15 | 32,786 | 2,988,444 | 152,090 | 184.9 K to 152.1 K (-17.73 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 42,614 | 0 | 184,876 | 142.3 K to 184.9 K (+29.95 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 12,592 | 0 | 142,262 | 129.7 K to 142.3 K (+9.71 %) |
| Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 76.02 | 248 | 18,854 | 129,670 | 129.4 K to 129.7 K (+0.19 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | A | 84.05 | 68,600 | 5,765,830 | 68,600 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | A | 84.05 | 235,820 | 19,820,671 | 235,820 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | A | 84.05 | 85,750 | 7,207,288 | 85,750 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | A | 84.05 | 128,630 | 10,811,352 | 128,630 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 1,000,000 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 84.35 | 400 | 33,739 | 3,948,066 | 3.9 M to 3.9 M (-0.01 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 83.77 | 55,973 | 4,688,590 | 3,948,466 | 4 M to 3.9 M (-1.40 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 82.98 | 43,627 | 3,620,147 | 4,004,439 | 4 M to 4 M (-1.08 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 16.40 | 100,000 | 1,639,500 | 4,048,066 | 3.9 M to 4 M (+2.53 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | A | 84.05 | 42,880 | 3,604,064 | 42,880 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 1,818 | 73,738 | 8,437 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 24.91 | 182 | 4,533 | 38,641 | |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 82.32 | 2,000 | 164,640 | 48,783 | 50.8 K to 48.8 K (-3.94 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 1,818 | 73,738 | 50,783 | 49 K to 50.8 K (+3.71 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 24.91 | 182 | 4,533 | 48,965 | 48.8 K to 49 K (+0.37 %) |
| Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | A | 84.05 | 75,030 | 6,306,272 | 75,030 |